1st Edition
Antiangiogenic Cancer Therapy
876 Pages
by
CRC Press
876 Pages
by
CRC Press
864 Pages
by
CRC Press
Also available as eBook on:
Top Investigators Explore the Complexities of Angiogenesis Cancer Research The targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies. However, as of yet, no antiangiogenic agent used as a monotherapy has demonstrated a survival benefit in a randomized Phase III trial. The combination of bevacizumab, the first FDA approved angiogenesis inhibitor,... Read more
Angiogenesis in Cancer; Targeting Angiogenesis for Cancer Therapy; Translating Angiogenesis Inhibitors to the Clinic; Treatment of Specific Cancers with Angiogenesis Inhibitors
Biography
Darren W. Davis, Roy S. Herbst, James L. Abbruzzese
